FLXN

Flexion Therapeutics Inc

A biopharmaceutical company, founded in 2007 by two former Eli Lilly executives, that developed non-opioid pain treatments for musculoskeletal conditions. Its flagship product, Zilretta, is an extended-release injectable steroid that became the first of its kind approved by the FDA in 2017 to manage osteoarthritis knee pain with a single injection. The company was bought by Pacira BioSciences in 2021, and its name hints at its focus on flexible joint movement.

No Schedule 13D or 13G filings recorded.